Mar 13, 2023 07:00AM
Mar 13, 2023 06:56AM
Feb 23, 2023 08:30AM
Feb 13, 2023 07:30AM
Feb 2, 2023 04:01PM
Jan 5, 2023 04:01PM
Jan 5, 2023 04:01PM Provention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors
Nov 17, 2022 05:46PM
Nov 17, 2022 05:45PM
Nov 3, 2022 07:00AM
Oct 13, 2022 07:30AM
Oct 6, 2022 08:13AM
Oct 6, 2022 07:00AM
Aug 31, 2022 06:12PM Provention Bio Announces $125 Million Term Loan Facility with Hercules Capital
Aug 4, 2022 07:33AM
Aug 4, 2022 07:00AM
Jul 28, 2022 07:30AM
Jul 7, 2022 07:28PM
Jun 30, 2022 04:01PM
Jun 30, 2022 04:01PM
May 12, 2022 07:30AM Provention Bio to Host a May 19, 2022 Virtual Investor Event Focused on the Potential Commercial Launch of Teplizumab Later This Year
May 5, 2022 07:49AM
May 5, 2022 07:05AM
May 5, 2022 07:00AM
Apr 28, 2022 07:30AM
Mar 28, 2022 07:31AM
Mar 28, 2022 07:30AM
Mar 21, 2022 07:02AM Provention Bio Inc. (PRVB) Announces FDA Acceptance of the BLA Resubmission for Teplizumab for the Delay of Clinical Type 1 Diabetes in At-Risk Individuals
Mar 21, 2022 07:00AM
Feb 24, 2022 07:20AM
Feb 24, 2022 07:00AM
Feb 22, 2022 07:33AM
Feb 22, 2022 07:30AM
Feb 17, 2022 04:05PM
Jan 27, 2022 04:05PM Provention Bio Inc. (PRVB) is Resubmitting BLA for Delay of Clinical Type 1 Diabetes in At-Risk Individuals Following Type B Meeting with the FDA
Jan 27, 2022 04:05PM
Jan 20, 2022 04:05PM
Nov 22, 2021 07:31AM
Nov 22, 2021 07:30AM
Nov 17, 2021 07:30AM
Nov 5, 2021 04:30PM
Nov 4, 2021 07:53AM Provention Bio Inc. (PRVB) Tops Q3 EPS by 8c
Nov 4, 2021 07:07AM
Nov 4, 2021 07:05AM
Nov 4, 2021 07:00AM
Oct 28, 2021 07:30AM
Oct 26, 2021 07:35AM
Oct 26, 2021 07:30AM
Sep 13, 2021 07:35AM Provention Bio (PRVB) Provides Update on Potential Timing of Teplizumab At-Risk Type 1 Diabetes Biologics License Application Resubmission
Sep 13, 2021 07:30AM

1,168,522 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All